直接口服抗凝药患者静脉溶栓的安全性:系统综述与荟萃分析
结果显示,DOAC患者(包括48小时内服药者)静脉溶栓后症状性颅内出血风险并未增加。
要点
- 服用DOAC的AIS患者静脉溶栓后症状性颅内出血风险未显著增加
- 48小时内服用DOAC与未知间隔者结果一致,均无额外出血风险
- 使用依达赛珠单抗逆转者与未使用者出血转化及早期死亡风险无显著差异
核心结论
- 既往服用DOAC似乎不增加经筛选的急性缺血性卒中患者静脉溶栓后症状性颅内出血风险。
主要发现
- 48小时内服用DOAC与华法林相比,NINDS标准症状性颅内出血OR 0.55(95%CI 0.19-1.59),ECASS-II标准OR 0.77(95%CI 0.28-2.16)。
- 48小时内服用DOAC与未抗凝相比,NINDS标准OR 1.23(95%CI 0.46-3.31),ECASS-II标准OR 0.87(95%CI 0.32-2.41)。
- 无时间限制分析中,DOAC与华法林相比NINDS标准OR 0.85(95%CI 0.49-1.45),ECASS-II标准OR 1.11(95%CI 0.67-1.85)。
- 无时间限制分析中,DOAC与未抗凝相比NINDS标准OR 1.17(95%CI 0.43-3.15),ECASS-II标准OR 0.87(95%CI 0.33-2.41)。
- 纳入研究间无异质性(I2=0%)。
关键数值与推荐
- 主要结局为症状性颅内出血,分别采用NINDS与ECASS-II标准定义。
- 亚组分析包括DOAC末次服用至溶栓间隔≤48小时与未知间隔,以及是否使用逆转剂。
临床怎么用
- 对于经选择的服用DOAC的急性缺血性卒中患者,静脉溶栓前无需仅因DOAC服药史而常规排除。
- 决策时仍需结合末次服药时间、肾功能及逆转剂使用等个体化评估。
局限性
- DOAC组样本量较小(366例),研究数量有限(6项)。
- 为观察性研究的荟萃分析,存在选择偏倚可能。
- 仅123例提供了逆转剂使用细节,相关分析效力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- There are scarce data regarding the safety of intravenous thrombolysis (IVT) in acute ischemic stroke among patients on direct oral anticoagulants (DOACs). Methods- We performed a systematic review and meta-analysis of the current literature. Data regarding all adult patients pretreated with DOAC who received IVT for acute ischemic stroke were recorded. Meta-analysis was performed by comparing the rate of symptomatic intracerebral hemorrhage in these patients with (1) stroke patients without prior anticoagulation therapy and (2) patients on warfarin with international normalized ratio <1.7. Meta-analyses were further conducted in subgroups as follows: (1) administration of DOAC within 48 hours versus an unknown interval before IVT, (2) consideration of symptomatic intracerebral hemorrhage outcome according to the National Institute of Neurological Disorders (NINDS) versus the European Cooperative Acute Stroke Study II (ECASS-II) criteria. Results- After reviewing 13 392 reports and communicating with certain authors of 12 published studies, a total of 52 823 acute ischemic stroke patients from 6 studies were enrolled in the present meta-analysis: DOACs: 366, warfarin: 2133, and 503 241 patients without prior anticoagulation. We detected no additional risk of symptomatic intracerebral hemorrhage following IVT among patients taking DOACs within 48 hours-DOACs-warfarin: NINDS (odds ratio [OR], 0.55 [95% CI, 0.19-1.59]), ECASS-II (OR, 0.77 [95% CI, 0.28-2.16]); DOACs-no-anticoagulation: NINDS (OR, 1.23 [95% CI, 0.46-3.31]), ECASS-II (OR, 0.87 [95% CI, 0.32-2.41]). Similarly, no additional risk was detected with no time limit between last DOAC intake-DOACs warfarin: NINDS (OR, 0.85 [95% CI, 0.49-1.45]), ECASS-II (OR, 1.11 [95% CI, 0.67-1.85]); DOACs-no-anticoagulation: NINDS (OR, 1.17 [95% CI, 0.43-3.15]), ECASS-II (OR, 0.87 [95% CI, 0.33-2.41]). There was no evidence of heterogeneity across included studies (I2=0%). We also provided the details of 123 individual cases with or without reversal agents before IVT. There was no significant increase in the risk of hemorrhagic transformation (OR, 1.48 [95% CI, 0.50-4.38]), symptomatic hemorrhagic transformation (OR, 0.47 [95% CI, 0.09-2.55]), or early mortality (OR, 0.60 [95% CI, 0.11-3.43]) between cohorts who did or did not receive prethrombolysis idarucizumab. Conclusions- The results of our study indicated that prior intake of DOAC appears not to increase the risk of symptomatic intracerebral hemorrhage in selected AIS patients treated with IVT.
引用
- Shahjouei S, Tsivgoulis G, Goyal N, et al. Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. Stroke. 2019. PMID: 31884908. doi:10.1161/STROKEAHA.119.026426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。